As analysts monitor volatile markets in recent weeks they have updated their price targets on shares of Fate Therapeutics, Inc. (FATE).
Based on the latest notes released to investors, 3 analysts have issued a rating of “buy”, 4 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.

Latest broker research notes issued:

09/08/2017 – Leerink Swann began new coverage on Fate Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 7 price target on the stock.

03/20/2017 – Fate Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 6 price target on the stock.

03/17/2017 – Fate Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 7 price target on the stock.

03/17/2017 – Fate Therapeutics, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 7 price target on the stock.

09/22/2016 – Roth Capital began new coverage on Fate Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.

12/03/2015 – Wells Fargo began new coverage on Fate Therapeutics, Inc. giving the company a “outperform” rating.

11/04/2015 – Fate Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen.

10/06/2015 – Raymond James began new coverage on Fate Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 8 price target on the stock.

05/12/2015 – Fate Therapeutics, Inc. was downgraded to “hold” by analysts at Zacks. They now have a USD 6.25 price target on the stock.

The share price of Fate Therapeutics, Inc. (FATE) was unchanged +0.00% during the last trading session, with a day high of 4.33. 198053 shares were traded on Fate Therapeutics, Inc.’s last session.

The stock’s 50 day moving average is 3.20 and its 200 day moving average is 3.74. The stock’s market capitalization is 173.94M. Fate Therapeutics, Inc. has a 52-week low of 1.80 and a 52-week high of 5.68.

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.